alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Amplification'],"[{'ncitCode': 'C49176', 'drugName': 'Palbociclib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 164, 'code': 'DDLS', 'color': 'LightYellow', 'name': 'Dedifferentiated Liposarcoma', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'LIPO', 'level': 3, 'tumorForm': 'SOLID'}",[],"['37343202', '27124835', '23569312']",[],"Palbociclib and abemaciclib are small molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) that prevent downstream degradation of the RB tumor suppressor protein and are FDA-approved for use in patients with estrogen receptor-positive breast cancer. The NCCN recommends palbociclib as category 2A for patients with well-differentiated/dedifferentiated liposarcoma (WD-DDLS) based on the results of a Phase II study of palbociclib in CDK4-amplified, RB-positive WD-DDLS which showed a twelve-week progression-free survival of 66%, significantly exceeding the progression-free survival (PFS) goal of 40% (PMID: 23569312). A second phase II trial of palbociclib in patients with CDK4-amplified, RB-positive WD-DDLS showed that even with a lower dose of palbociclib, progression-free survival at twelve weeks was 57.2% (95% CI=42.4%-68.8%), which included one patient with a complete response (PMID: 27124835). In a case report, a patient with CDK4-amplified and MDM2-amplified WD-DDLS was treated with abemaciclib and demonstrated partial radiologic and near-complete pathological response (PMID: 37343202)."
['Amplification'],"[{'ncitCode': 'C49176', 'drugName': 'Palbociclib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 41, 'code': 'WDLS', 'color': 'LightYellow', 'name': 'Well-Differentiated Liposarcoma', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'LIPO', 'level': 3, 'tumorForm': 'SOLID'}",[],"['37343202', '27124835', '23569312']",[],"Palbociclib and abemaciclib are small molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) that prevent downstream degradation of the RB tumor suppressor protein and are FDA-approved for use in patients with estrogen receptor-positive breast cancer. The NCCN recommends palbociclib as category 2A for patients with well-differentiated/dedifferentiated liposarcoma (WD-DDLS) based on the results of a Phase II study of palbociclib in CDK4-amplified, RB-positive WD-DDLS which showed a twelve-week progression-free survival of 66%, significantly exceeding the progression-free survival (PFS) goal of 40% (PMID: 23569312). A second phase II trial of palbociclib in patients with CDK4-amplified, RB-positive WD-DDLS showed that even with a lower dose of palbociclib, progression-free survival at twelve weeks was 57.2% (95% CI=42.4%-68.8%), which included one patient with a complete response (PMID: 27124835). In a case report, a patient with CDK4-amplified and MDM2-amplified WD-DDLS was treated with abemaciclib and demonstrated partial radiologic and near-complete pathological response (PMID: 37343202)."
['Amplification'],"[{'ncitCode': 'C97660', 'drugName': 'Abemaciclib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 164, 'code': 'DDLS', 'color': 'LightYellow', 'name': 'Dedifferentiated Liposarcoma', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'LIPO', 'level': 3, 'tumorForm': 'SOLID'}",[],"['37343202', '27124835', '23569312']",[],"Palbociclib and abemaciclib are small molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) that prevent downstream degradation of the RB tumor suppressor protein and are FDA-approved for use in patients with estrogen receptor-positive breast cancer. The NCCN recommends palbociclib as category 2A for patients with well-differentiated/dedifferentiated liposarcoma (WD-DDLS) based on the results of a Phase II study of palbociclib in CDK4-amplified, RB-positive WD-DDLS which showed a twelve-week progression-free survival of 66%, significantly exceeding the progression-free survival (PFS) goal of 40% (PMID: 23569312). A second phase II trial of palbociclib in patients with CDK4-amplified, RB-positive WD-DDLS showed that even with a lower dose of palbociclib, progression-free survival at twelve weeks was 57.2% (95% CI=42.4%-68.8%), which included one patient with a complete response (PMID: 27124835). In a case report, a patient with CDK4-amplified and MDM2-amplified WD-DDLS was treated with abemaciclib and demonstrated partial radiologic and near-complete pathological response (PMID: 37343202)."
['Amplification'],"[{'ncitCode': 'C97660', 'drugName': 'Abemaciclib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 41, 'code': 'WDLS', 'color': 'LightYellow', 'name': 'Well-Differentiated Liposarcoma', 'mainType': {'id': None, 'name': 'Soft Tissue Sarcoma', 'tumorForm': 'MIXED'}, 'tissue': 'Soft Tissue', 'children': {}, 'parent': 'LIPO', 'level': 3, 'tumorForm': 'SOLID'}",[],"['37343202', '27124835', '23569312']",[],"Palbociclib and abemaciclib are small molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) that prevent downstream degradation of the RB tumor suppressor protein and are FDA-approved for use in patients with estrogen receptor-positive breast cancer. The NCCN recommends palbociclib as category 2A for patients with well-differentiated/dedifferentiated liposarcoma (WD-DDLS) based on the results of a Phase II study of palbociclib in CDK4-amplified, RB-positive WD-DDLS which showed a twelve-week progression-free survival of 66%, significantly exceeding the progression-free survival (PFS) goal of 40% (PMID: 23569312). A second phase II trial of palbociclib in patients with CDK4-amplified, RB-positive WD-DDLS showed that even with a lower dose of palbociclib, progression-free survival at twelve weeks was 57.2% (95% CI=42.4%-68.8%), which included one patient with a complete response (PMID: 27124835). In a case report, a patient with CDK4-amplified and MDM2-amplified WD-DDLS was treated with abemaciclib and demonstrated partial radiologic and near-complete pathological response (PMID: 37343202)."
